USP Still Has a Long Way to Go in Updating Excipient Monographs
This article was originally published in The Gold Sheet
Executive Summary
U.S. Pharmacopeia officials say they have only modernized about 10% of the excipient monographs deemed a high priority in need of modernization by FDA and have received “minimal” input from industry in updating outdated monographs.
You may also be interested in...
‘Asbestos-Free’ A Relative Term? SAI Testing Expert On Cosmetic Talc Challenges
Transmission electron microscopy is likely the safest bet, among other imaging technologies, for companies looking to verify their cosmetic talc as asbestos-free. However, there’s no regulatory-mandated method for cosmetics purposes, which may explain conflicting results being reported by different labs.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.